NASHUA, N.H.--(BUSINESS WIRE)--iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported strong adoption of its latest deep-learning, cancer detection software solution for digital breast tomosynthesis (DBT), ProFound AI™. The powerful solution built on artificial intelligence (AI) delivers critical benefits to radiologists, their facilities and patients in identifying cancer earlier.
“ProFound AI for DBT is like having another radiologist right there in the reading room with you,” said Randy Hicks, M.D., MBA, radiologist, co-owner and CEO at Regional Medical Imaging. “It’s software you can trust to help diagnose cancers and improve workflow, keeping physicians on track and enabling them to read cases more quickly.”
Since the product was launched in the United States in December 2018, ProFound AI has been adopted by a significant number of high-profile hospitals and imaging centers in all major geographic areas of the country, demonstrating the strong need for such revolutionary technology.
Universal Medical provides the very best new & refurbished gamma cameras, quality parts & repair services. We also rebuild & replace camera detectors, move camera systems across town or across the country. Call us at 888-239-3510
“We are very pleased with the preliminary success and strong adoption of ProFound AI among some of the top luminary sites in the U.S.,” said Stacey Stevens, executive vice president and chief strategy and commercial officer at iCAD. “This strong initial adoption of ProFound AI now allows us to create powerful reference sites, customer testimonials and educational events that will further accelerate growth of this unprecedented solution. As the only FDA cleared provider of AI technology for digital breast tomosynthesis, we look forward to driving continued adoption, ultimately transforming breast cancer detection and improving patient lives.”
ProFound AI is a high-performance, deep-learning, cancer detection and workflow solution for DBT delivering critical benefits to radiologists, their facilities, and their patients through the improvement of cancer detection rates by an average of 8 percent and decreasing unnecessary patient recall rates by an average of 7 percent. The new technology has been trained to detect malignant soft-tissue densities and calcifications. It also provides radiologists with scoring information representing the likelihood that a detection or case is malignant based on the large dataset of clinical images used to train the algorithm.
“Following our recent implementation of ProFound AI from iCAD, we have already recognized the value and benefits it is providing to us in reading our DBT studies. Our radiologists appreciate this compelling technology and the high sensitivity and specificity it delivers in identifying lesion markings. It is imperative for us to continue providing the community with the best technology available to detect breast cancer, and our use of ProFound AI is indicative of this,” said Harold Tanenbaum, M.D., radiologist, medical director Marine Park Radiology, NY.
In addition to improving clinical performance related to breast cancer detection and false positive rates, study results showed that ProFound AI can reduce radiologists’ reading time by more than 50 percent on average. An increase in reading time has been a significant challenge for radiologists when moving from 2D to 3D mammography.
“We are proud to be using ProFound AI for DBT to assist our radiology team in providing improved quality patient care. Timing is critical for patients with hidden breast cancers, and the combination of 3D mammography and iCAD’s ProFound AI software could be life saving,” said John Ervin, imaging director for Hunt Regional Healthcare.
ProFound AI is currently available for use with leading DBT systems in the U.S., Canada and Europe.
About iCAD, Inc.
Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions.